gdc
Breast CancerSurvivorship

Do We Become Complacent Survivors After a Few Years of Cancer Remission?

Breast cancer survivor Ginger Modiri cautions those in remission to avoid becoming complacent and to keep up with their follow-up screenings.
October 2018 Vol 4 No 5
Ginger Modiri
6-year breast cancer survivor
San Juan Capistrano, CA
Ginger (center) surrounded by her family during Race for the Cure
Ginger (center) surrounded by her family during Race for the Cure, 9/2/18, in California.

Do we as cancer survivors tend to become complacent about our recovering health after several years? Is it easier to say, “Let sleeping dogs lie?”

I recently heard a “snip-it” from an article published by the National Comprehensive Cancer Network (or NCCN) titled “Adherence to Guidelines for Breast Surveillance in Breast Cancer Survivors.”1

I was amazed to hear how many cancer survivors are failing to keep up with their long-term routine follow-up mammograms, according to the article.

Granted, most of us, including this survivor, don’t look forward to the scans, blood tests, or other types of testing. But we must keep reminding ourselves that follow-up is a necessary part of our continued recovery.

Surrounding ourselves in false reality may seem easier at the time, but dealing with the inevitable need for testing is a much healthier mindset.

Putting off routine service to our cars, computers, and appliances only leads to increased damage in deferred maintenance, usually costing us more financially.

Cutting years of life off ones’ machines is not the end of the world. Failing to adhere to strict routines regarding a survivor’s medical tests can prematurely be the end of the world for a human being.

Scheduling my mammograms, blood tests, colonoscopies, and other tests is pretty much a no-brainer; I tend to book those appointments around my birthday each year.

Why, you may ask? “It’s my birthday, and testing is the best gift I can give to myself.”

Reference

1. Ruddy KJ, Sangaralingham L, Freedman RA, et al. Adherence to guidelines for breast surveillance in breast cancer survivors. Journal of the National Comprehensive Cancer Network. 2018;16(5):526-534.

Recommended For You
Survivorship
Patients as Innovators: The Future of Medical Device Development
By Cinde Dolphin
Reading Cinde Dolphin’s description of how she and other patients with cancer are inventing simple, but very useful, solutions to improve their cancer treatment needs may inspire you to become an inventor, to help yourself or other people with cancer.
Breast CancerFDA Approvals, News & Updates
Piqray New Treatment Approved for Metastatic Breast Cancer and PI3KCA Mutation
In May 2019, the FDA approved Piqray (alpelisib), the first PI3K inhibitor for the treatment of metastatic breast cancer with a PI3KCA mutation in postmenopausal women, and in men. An FDA spokesperson said it was the first treatment “to demonstrate a clinically meaningful benefit” for this type of breast cancer.
Last modified: January 3, 2019

Subscribe to CONQUER: the patient voice® magazine

Receive timely cancer news & updates, patient stories, and more.

Country